<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159055</url>
  </required_header>
  <id_info>
    <org_study_id>280303-HMO-CTIL</org_study_id>
    <nct_id>NCT00159055</nct_id>
  </id_info>
  <brief_title>Adoptive Immunotherapy for CMV Disease</brief_title>
  <official_title>Prevention and Treatment of CMV Disease by Adoptive Immunotherapy With Immune Donor Lymphocytes in Conjunction With Non-myeloablative Stem Cell Transplantation (NST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      Treatment strategy of patients:&#xD;
&#xD;
      Stem cell engraftment (myeloablative or NST) for induction of host vs graft myeloablative&#xD;
      transplantation tolerance.&#xD;
&#xD;
      Whenever indicated, additional post NST DLI given in graded increment, to optimize control of&#xD;
      GVHD.&#xD;
&#xD;
      Preparation of immune donor lymphocytes, either by donor immunization in-vitro with a&#xD;
      CMV-specific peptide followed by administration of immunized donor lymphocytes, or by&#xD;
      injection of donor lymphocytes and in-vivo sensitization of donor lymphocytes in the patient&#xD;
      following DLI.&#xD;
&#xD;
      Pre-emptive treatment of seronegative patients at risk or patients with documented viremia or&#xD;
      CMV disease with CMV-specific donor lymphocytes generated in-vivo in the donor or in the host&#xD;
      by peptide immunization.&#xD;
&#xD;
      Consenting donors will be immunized with CMV-specific peptides, for induction of CTLs in-vivo&#xD;
      following subcutaneous inoculation of peptides with adjuvant or donor APC pulsed with&#xD;
      relevant peptides.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    the PI is no longer work at Hadassah&#xD;
  </why_stopped>
  <start_date>February 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induce and amplify T cell-mediated immunotherapy against cytomegalovirus (CMV) infection in stem cell allograft recipients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate toxicity of the procedure.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CMV Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Patient:&#xD;
&#xD;
          -  Consenting patients with indication for myeloablative BMT or NST with an HLA matching&#xD;
             sibling available, for transplant.&#xD;
&#xD;
          -  Patients at risk of CMV disease including seronegative patients; patients with&#xD;
             seronegative donors, and seronegative donor for sero positive patients.&#xD;
&#xD;
          -  Patients with resistant CMV viremia or CMV disease not responding to conventional&#xD;
             treatment with ganciclovir, or Foscarnet.&#xD;
&#xD;
          -  Patients with HLA phenotype for which a relevant peptide for CMV exists.&#xD;
&#xD;
          -  For Donor:&#xD;
&#xD;
          -  Consenting sibling &gt;18 years old.&#xD;
&#xD;
          -  HLA phenotype for which a relevant peptide for CMV exists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For Patient:&#xD;
&#xD;
          -  Patients with severe resistant GVHD where there may be a risk to administer DLI or&#xD;
             immunized donor lymphocytes.&#xD;
&#xD;
          -  For Donor:&#xD;
&#xD;
          -  Consenting sibling &gt;18 years old.&#xD;
&#xD;
          -  HLA phenotype for which a relevant peptide for CMV exists.&#xD;
&#xD;
          -  Donor with an infectious disease (e.g. HIV-1; HBV, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shimon Slavin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

